Prof. dr hab. n. med. Piotr Buszman

Kadra zarządzająca

Rada Doradcza

partner with us

Improving the lives of patients by developing proprietary, innovative

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal

Our Partners

Merck

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Pfizer Eastern Europe

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Alcon

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Community Foundation

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.